Welcome to ProBioGen
ProBioGen AG is a renowned Contract Development and Manufacturing Organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis. ProBioGen also provides process development services and manufacturing technologies for viral vaccines.
With almost 25 years of experience in mammalian cell culture, combined with innovative scientific excellence and a strong intellectual property base, we cover the entire drug development value chain end-to-end.
1994 – ProBioGen founded as a diagnostic company
2000 – Strategic shift towards therapeutic protein contract development and GMP manufacturing
2001 – Cell line development platform established
2002 – Manufacturing authorization granted, using single-use bioreactors right from the beginning
2003 – First client designer cell line developed
2005 – More than 15 patent families granted
2008 – First commercial license for AGE1.CR duck cell line
2010 – Strategic Investor: Minapharm Pharmaceuticals
2011 – First commercial license given for GlymaxX® ADCC enhancement technology
2013 – First product produced with ProBioGen CHO cell line entered the market
2016 – First product produced on AGE1.CR® duck cell line entered the market
2017 – More than 400 stable cell lines developed
Global Customer Base
We are the partner of choice for biopharmaceutical companies relying on high quality cell line development and manufacturing capabilities. Our partners value our outstanding service quality, combined with variable project and deal structures, our quick responses and our flexibility.
Our clients benefit from custom-tailored projects designed to minimize development risks and ensure a successful outcome. Our experienced and flexible team of scientists, engineers, and technicians draws its motivation from the success of our clients’ projects. We are a reliable and agile partner in developing our clients’ products to the benefit of patients worldwide.
A new building is currently refurbished to house 1000L single-use bioreactor lines to keep up with the ever-increasing demand from our clients, starting operation in 2018.